共 47 条
Codelivery of Adriamycin and P-gp Inhibitor Quercetin Using PEGylated Liposomes to Overcome Cancer Drug Resistance
被引:32
作者:
Yu, Jiaqi
[1
]
Chen, Hao
[1
]
Jiang, Linxia
[1
]
Wang, Jianhong
[1
]
Dai, Jundong
[1
]
Wang, Jie
[1
]
机构:
[1] Beijing Univ Chinese Med, Sch Chinese Mat Med, Beijing 100102, Peoples R China
基金:
中国国家自然科学基金;
关键词:
Adriamycin;
quercetin;
anti-multidrug resistance;
long-circulating compound liposomes;
codelivery;
pharmacology;
BREAST-CANCER;
INDUCED CARDIOTOXICITY;
MULTIDRUG-RESISTANCE;
DOXORUBICIN;
DELIVERY;
BIOAVAILABILITY;
CELLS;
RATS;
PHARMACOKINETICS;
CHEMOSENSITIVITY;
D O I:
10.1016/j.xphs.2018.12.016
中图分类号:
R914 [药物化学];
学科分类号:
100701 ;
摘要:
Transmembrane protein P-gp's overexpression at the drug-resistant cell membrane is the most important characteristic of multidrug resistance (MDR). Quercetin (QUE) can effectively suppress the function of P-gp to reverse MDR. This study uses QUE as the P-gp inhibitor andfilm-ultrasound technique with ammonium sulfate transmembrane gradient method to prepare long-circulating liposomes simultaneously encapsulating QUE and Adriamycin (doxorubicin) (AMD/DOX). The optimal conditions for the preparation of AMD_QUE_long-circulating liposomes (SLs) are as follows:hydrogenated soybean phospholipids (HSPC):cholesterol:DSPE-PEG 2000 = 73.07:24.36:2.57 mol/mol, QUE:HSPC = 1:20 mol/mol, AMD:HSPC = 1:7.9 w/w (NH4)(2)SO4 0.15 mol/L, drug loaded (AMD) at 55 degrees C for 25 min). The average encapsulation efficiency of AMD and QUE was 97.49% and 95.50%, respectively. The average particle size is 85 nm (n = 3), and the average zeta potential is -14.9 mV. First, the pharmacokinetic study proved that codelivery liposomes enveloping QUE and AMD (AMD_QUE_SL) can obviously increase the blood concentration of AMD (C-max: 140.50 +/- 32.37 mu g/mL) and extend the half-life period of AMD in plasma (t(1/2):14.02 +/- 1.54 h). Second, AMD_QUE_SL can obviously enhance the cell toxicity to AMD-resistant cell strains (HL-6/ADR and MCF-7/ADR), and the reverse effects on the resistance of HL-6/ADR and MCF-7/ADR is increased to 4.81-fold and 3.21-fold, respectively. Third, according to the in vivo pharmacodynamic study, the relative tumor volume and relative tumor growth of the AMD_QUE_SL group were the lowest. The inhibition rate of tumor growth of this group was the highest. It can be concluded that AMD_QUE_SL can effectively reverse MDR, lower cardiac toxicity of AMD in clinical treatment, and improve the clinical treatment effect of AMD. (c) 2019 American Pharmacists Association (R). Published by Elsevier Inc. All rights reserved.
引用
收藏
页码:1788 / 1799
页数:12
相关论文